BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: As per the latest survey by Fact.MR, the global cardiopulmonary stress testing systems market is expected to register healthy growth, expanding at a CAGR of 4.8% over the forecast period from 2020 to 2025.

Fact.MR – A Market Research and Competitive Intelligence Provider: Fact.MR in its latest market analysis forecasts that the cardiac ablation technologies market will register high growth during the forecast period.

Artios Pharma Limited, a leading biotech company pioneering the development of novel small molecule therapeutics that target the DNA Damage Response process in order to treat patients suffering from a broad range of cancers, announces it has dosed the first patient in its Phase 1/2a study with its polymerase theta inhibitor, ART4215.

Tiziana Life Sciences plc announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 100,000 ordinary shares of 3p each in the market at a price of 52p per share.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that it will be participating at the Lytham Partners Fall 2021 Investor Conference on Tuesday, October 5, 2021 at 11:45 am.

Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma”, “First Wave”, or the “Company”), today announced that it has begun screening patients for enrollment in a Phase 2b clinical trial investigating a topical formulation of FW-UP as a potential treatment for ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS).

Thermo Fisher Scientific, the world leader in serving science, today announced that within booth #1322 inside the Atlanta World Congress Center it is showing its expanding portfolio of instruments, assays, controls and related technologies for increasing speed, performance and flexibility within clinical and research labs.

Lobe Sciences Ltd. (“Lobe” or the “Company”) (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical research studies, in established rodent models of mild traumatic brain injury/concussion (“mTBI”) and post-traumatic stress disorder (“PTSD”), using psilocybin plus N-Acetylcysteine (“NAC”).

Koya Medical received Food and Drug Administration (FDA) 510(k) clearance for its Dayspring ® Lite treatment for lymphedema and venous disease.